Agrawal Sushma, Mohan Lalit, Mourya Chandan, Neyaz Zafar, Saxena Rajan
Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India E-mail :
Asian Pac J Cancer Prev. 2016;17(4):2137-40. doi: 10.7314/apjcp.2016.17.4.2137.
Gall bladder cancer (GBC) usually presents as unresectable or metastatic disease. We conducted a feasibility study to evaluate the effect of neoadjuvant therapy (NAT) on radiologic downstaging and resectability in unresectable GBC cases.
Patients with locally advanced disease were treated with chemoradiotherapy [CTRT] ( external radiotherapy (45Gy) along with weekly concurrent cisplatin 35mg/ m2 and 5-FU 500 mg) and those with positive paraaortic nodes were treated with neoadjuvant chemotherapy [NACT (cisplatin 25mg/m2 and gemcitabine 1gm/m2 day 1 and 8, 3 weekly for 3 cycles). Radiological assessment was according to RECIST criteria by evaluating downstaging of liver involvement and lymphadenopathy into complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).
A total of 40 patients were evaluated from January 2012 to December 2014 (CTRT=25, NACT=15). Pretreatment CT scans revealed involvement of hilum (19), liver infiltration (38), duodenum involvement (n=22), colon involvement (n=11), N1 involvement (n=11), N2 disease (n=8), paraaortic LN (n=15), and no lymphadenopathy (n=6). After neoadjuvant therapy, liver involvement showed CR in 11(30%), PR in 4 (10.5%), SD in 15 (39.4%) and lymph node involvement showed CR in 17 (50%), PR in 6 (17.6%), SD in 4 (11.7 %). Six patients (CTRT=2, NACT=4) with 66.6 % and 83% downstaging of liver and lymphnodes respectively underwent extended cholecystectomy. There was 16.6 % and 83.3% rates of histopathological CR of liver and lymph nodes. All resections were R0.
Neoadjuvant therapy in unresectable gall bladder cancer results in a 15% resectability rate. This approach has a strong potential in achieving R0 and node negative disease. Radiologic downstaging (CR+PR) of liver involvement is 40.5% and lymphadenopathy is 67.5%. Nodal regression could serve as a predictor of response to neoadjuvant therapy.
胆囊癌(GBC)通常表现为不可切除或转移性疾病。我们开展了一项可行性研究,以评估新辅助治疗(NAT)对不可切除GBC病例的放射学降期和可切除性的影响。
局部晚期疾病患者接受放化疗[CTRT](外照射放疗(45Gy),同时每周顺铂35mg/m²和5-氟尿嘧啶500mg),腹主动脉旁淋巴结阳性患者接受新辅助化疗[NACT(顺铂25mg/m²和吉西他滨1g/m²,第1天和第8天,每3周1次,共3个周期)]。放射学评估根据RECIST标准进行,通过评估肝脏受累和淋巴结病的降期情况分为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)。
2012年1月至2014年12月共评估了40例患者(CTRT组25例,NACT组15例)。治疗前CT扫描显示肝门受累(19例)、肝浸润(38例)、十二指肠受累(22例)、结肠受累(11例)、N1受累(11例)、N2期疾病(8例)、腹主动脉旁淋巴结受累(15例)和无淋巴结病(6例)。新辅助治疗后,肝脏受累显示CR 11例(30%)、PR 4例(10.5%)、SD 15例(39.4%),淋巴结受累显示CR 17例(50%)、PR 6例(17.6%)、SD 4例(11.7%)。6例患者(CTRT组2例,NACT组4例)肝脏和淋巴结分别有66.6%和83%的降期,接受了扩大胆囊切除术。肝脏和淋巴结的组织病理学CR率分别为16.6%和83.3%。所有切除均为R0切除。
不可切除胆囊癌的新辅助治疗可使可切除率达到15%。这种方法在实现R0切除和淋巴结阴性疾病方面具有很大潜力。肝脏受累的放射学降期(CR+PR)为40.5%,淋巴结病为67.5%。淋巴结退缩可作为新辅助治疗反应的预测指标。